

News in LUTS pharmacotherapy

Poster Session 40

Sunday, 26 March  
14:00 - 15:30

**Location:** Room Milan, North Hall (Level 1)

**Chairs:** J.C. Nickel, Kingston (CA)  
P. Nyirády, Budapest (HU)  
N. Thiruchelvam, Cambridge (GB)

**Aims and objectives of this session**

The objectives of this session is to understand how new pharmacologic research will impact on our understanding of LUTS and learn to use this knowledge to improve our management of storage and voiding LUTS associated with benign prostatic hyperplasia, overactive bladder and other causes of LUTS.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (\*) are 3 minutes in length, followed by 3 minutes for discussion.

- \*531 **Impact of 5-alpha reductase inhibitors for treatment of benign prostatic hyperplasia on erectile dysfunction, treated depression, gynecomastia, and breast cancer: A real world 20 year observational study**  
By: Hagberg K.W.<sup>2</sup>, Divan H.A.<sup>3</sup>, Persson R.<sup>2</sup>, Fang S.C.<sup>3</sup>, Jick S.S.<sup>2</sup>, Nickel J.C.<sup>1</sup>  
**Institutes:**<sup>1</sup>Queen's University, Dept. of Urology, Kingston, Canada, <sup>2</sup>Boston University School of Public Health, Boston Collaborative Drug Surveillance Program, Lexington, United States of America, <sup>3</sup>New England Research Institutes, NERI, Watertown, United States of America
- 532 **Phosphodiesterase inhibitors for BPH-LUTS: Is the benefit worth it?**  
By: Pattanaik S.<sup>1</sup>, Mayuduru R.<sup>2</sup>, Panda A.<sup>3</sup>, Mathew J.<sup>4</sup>, Aggarwal M.<sup>5</sup>, Singh S.<sup>2</sup>, Mandal A.<sup>2</sup>  
**Institutes:**<sup>1</sup>Postgraduate Institute of Medical Education and Research, Dept. of Pharmacology, Chandigarh, India, <sup>2</sup>Postgraduate Institute of Medical Education and Research, Dept. of Urology, Chandigarh, India, <sup>3</sup>CMC, Dept. of Urology, Vellore, India, <sup>4</sup>Postgraduate Institute of Medical Education and Research, Dept. of Pediatrics, Chandigarh, India, <sup>5</sup>NMC Specialty Hospital, Dept. of Urology, Abudhabi, United Arab Emirates
- \*533 **Antimuscarinic use in the elderly: A poisoned apple?**  
By: Meyer C.<sup>1</sup>, Pucheril D.<sup>2</sup>, Karabon P.<sup>2</sup>, Gild P.<sup>1</sup>, Von Landenberg N.<sup>1</sup>, Atiemo H.<sup>2</sup>, Menon M.<sup>2</sup>, Chughtai B.<sup>3</sup>, Fisch M.<sup>4</sup>, Chun F.<sup>4</sup>, Trinh Q-D.<sup>1</sup>  
**Institutes:**<sup>1</sup>Brigham and Women's Hospital, Harvard Medical School, Division of Urological Surgery and Center For, Division of Urologic Surgery and Center For Surgery and Public Health, Boston, United States of America, <sup>2</sup>Henry Ford Health System, VUI Center for Outcomes Research, Analytics and Evaluation, Vattikuti Urology Institute, Detroit, United States of America, <sup>3</sup>Weil Cornell Medical College/New York Presbyterian Hospital, Dept. of Urology, New York, United States of America, <sup>4</sup>University Medical Center Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany
- 534 **A 52-week randomized comparative study of a triple therapy (tamsulosin, dutasteride, and imidafenacin) versus a dual therapy (tamsulosin and dutasteride) in benign prostatic hyperplasia patients with overactive bladder (DirecT Study)**  
By: Yamanishi T.<sup>1</sup>, Asakura H.<sup>2</sup>, Seki N.<sup>3</sup>, Tokunaga S.<sup>4</sup>  
**Institutes:**<sup>1</sup>Dokkyo Medical University, Dept. of Urology, Tochigi, Japan, <sup>2</sup>Saitama Medical University Hospital, Dept. of Urology, Saitama, Japan, <sup>3</sup>Kyushu Central Hospital, Dept. of Urology, Fukuoka, Japan, <sup>4</sup>Kyushu University Hospital, Medical Information Center, Fukuoka, Japan

- 535 **Comparison between tadalafil 5 mg vs. Serenoa repens/selenium/lycopene for the treatment of benign prostatic lower urinary tract symptoms secondary to benign prostatic hyperplasia. A phase IV, randomized, multicenter, non-inferiority clinical study. SPRITE study**  
**By:** Morgia G.<sup>1</sup>, Vespasiani G.<sup>2</sup>, Reale G.<sup>1</sup>, Di Mauro M.<sup>1</sup>, Pareo R.<sup>3</sup>, Voce S.<sup>4</sup>, Madonia M.<sup>5</sup>, Fedelini P.<sup>6</sup>, Veneziano P.<sup>7</sup>, Carini M.<sup>8</sup>, Salvia G.<sup>9</sup>, Santaniello F.<sup>10</sup>, Ginepri A.<sup>11</sup>, Bitelli M.<sup>12</sup>, Terrone C.<sup>13</sup>, Gentile M.<sup>14</sup>, Giannantoni A.<sup>15</sup>, Blefari F.<sup>16</sup>, Beatrici V.<sup>17</sup>, Polledro P.<sup>18</sup>, La Rosa P.<sup>19</sup>, Arnone S.<sup>20</sup>, Santelli G.<sup>21</sup>, Russo G.I.<sup>1</sup>  
**Institutes:**<sup>1</sup>University of Catania, Urology Section, Dept. of Surgery, Catania, Italy, <sup>2</sup>University of Tor Vergata, Dept. of Urology, Rome, Italy, <sup>3</sup>Hospital Nuovo Regina Margherita Roma, Dept. of Urology, Rome, Italy, <sup>4</sup>Ravenna Hospital, Dept. of Urology, Ravenna, Italy, <sup>5</sup>University of Sassari, Dept. of Urology, Sassari, Italy, <sup>6</sup>Cardarelli Hospital, Dept. of Urology, Naples, Italy, <sup>7</sup>Riuniti Hospital, Dept. of Urology, Reggio Calabria, Italy, <sup>8</sup>University of Firenze, Dept. of Urology, Florence, Italy, <sup>9</sup>ASP Acireale, Dept. of Urology, Acireale, Italy, <sup>10</sup>Riuniti Hospital, Dept. of Urology, Ancona, Italy, <sup>11</sup>Figlie Di San Camillo Hospital, Dept. of Urology, Rome, Italy, <sup>12</sup>Frascati Hospital, Dept. of Urology, Frascati, Italy, <sup>13</sup>University of Piemonte Orientale, Dept. of Urology, Novara, Italy, <sup>14</sup>Avellino Hospital, Dept. of Urology, Avellino, Italy, <sup>15</sup>University of Perugia, Dept. of Urology, Perugia, Italy, <sup>16</sup>Hospital of Prato, Dept. of Urology, Prato, Italy, <sup>17</sup>S. Croce Hospital, Dept. of Urology, Ancona, Italy, <sup>18</sup>SS. Annunziata Di Savigliano Hospital, Dept. of Urology, Cuneo, Italy, <sup>19</sup>Garibaldi Hospital, Dept. of Urology, Catania, Italy, <sup>20</sup>Lugo of Romagna Hospital, Dept. of Urology, Ravenna, Italy, <sup>21</sup>Lucca Hospital, Dept. of Urology, Lucca, Italy
- 536 **A randomized, open-label, multicenter study evaluating efficacy of switch from dutasteride to tadalafil in benign prostatic hyperplasia patient with lower urinary tract symptoms (D-to-T trial)**  
**By:** Matsumoto T.<sup>1</sup>, Hatakeyama S.<sup>1</sup>, Yoshikawa K.<sup>2</sup>, Fukui K.<sup>3</sup>, Yanagisawa T.<sup>4</sup>, Kawaguchi T.<sup>5</sup>, Imai A.<sup>1</sup>, Yoneyama T.<sup>1</sup>, Hashimoto Y.<sup>1</sup>, Koie T.<sup>1</sup>, Saito H.<sup>6</sup>, Yamaya K.<sup>6</sup>, Funyu T.<sup>6</sup>, Ohyama C.<sup>1</sup>  
**Institutes:**<sup>1</sup>Hirosaki University Graduate School of Medicine, Dept. of Urology, Hirosaki, Japan, <sup>2</sup>Mutsu General Hospital, Dept. Of Urology, Mutsu, Japan, <sup>3</sup>Fukui Urology Clinic, Dept. of Urology, Aomori, Japan, <sup>4</sup>Aomori Rosai Hospital, Dept. of Urology, Hachinohe, Japan, <sup>5</sup>Aomori Prefectural Central Hospital, Dept. of Urology, Aomori, Japan, <sup>6</sup>Oyokyo Kidney Research Institute, Dept. of Urology, Hirosaki, Japan
- 538 **Impact of Vesomni™ on quality of life of men with lower urinary tract symptoms associated with benign prostatic hyperplasia in routine clinical practice: Interim results from the EUROPA study**  
**By:** Rees J.<sup>1</sup>, Arbe E.<sup>7</sup>, Rosa Arias J.<sup>2</sup>, Skoumal R.<sup>3</sup>, Walters C.<sup>4</sup>, Yavuz Y.<sup>5</sup>, De Wachter S.<sup>6</sup>  
**Institutes:**<sup>1</sup>Tyntesfield Medical Group, Brockway Medical Centre, Nailsea, United Kingdom, <sup>2</sup>Hospital "Santiago Apóstol", Dept. of Urology, Miranda De Ebro, Spain, <sup>3</sup>Urocentrum Brno, Dept. of Urology, Brno, Czech Republic, <sup>4</sup>Astellas Pharma Europe Ltd, Medical and Clinical Operations, Chertsey, United Kingdom, <sup>5</sup>Astellas Pharma Global Development, Dept. of Data Sciences, Leiden, The Netherlands, <sup>6</sup>University Hospital Antwerpen, University Antwerpen, Dept. of Urology, Edegem, Belgium, <sup>7</sup>Astellas Pharma Europe Ltd, Dept. of Medical Affairs, Chertsey, United Kingdom
- 539 **Post-operative continuous use of antimuscarinics in BPH patients with storage symptoms requiring antimuscarinics before surgery – a nationwide population-based study**  
**By:** Huang E.Y.-H., Chung H.-J., Lin C.-C., Peng R.-S., Chang Y.-H., Lin A.T.-L., Chen K.-K.  
**Institutes:**Taipei Veterans General Hospital, Dept. of Urology, Taipei, Taiwan
- 540 **A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms**  
**By:** Cho S.<sup>1</sup>, Hoon C.<sup>1</sup>, Park J.Y.<sup>1</sup>, Bae J.H.<sup>1</sup>, Lee K.W.<sup>2</sup>, Yoo T.K.<sup>3</sup>, Sin D.G.<sup>4</sup>, Kim S.W.<sup>5</sup>, Kim Y.H.<sup>2</sup>  
**Institutes:**<sup>1</sup>Korea University Anam Hospital, Dept. of Urology, Ansan, South Korea, <sup>2</sup>Bucheon Hospital, Soonchunhyang University, Dept. of Urology, Bucheon, South Korea, <sup>3</sup>Ulji University Nowon Hospital, Dept. of Urology, Seoul, South Korea, <sup>4</sup>Busan University Hospital, Dept. of Urology, Busan, South Korea, <sup>5</sup>Seoul University Hospital, Dept. of Urology, Seoul, South Korea
- 541 **Testosterone therapy (TTh) improves urinary function and reduces major adverse cardiovascular events (MACE) in hypogonadal men with type 2 diabetes (T2DM) treated up to 8 years in comparison to an untreated control group**  
**By:** Haider A.<sup>1</sup>, Haider K.<sup>1</sup>, Doros G.<sup>2</sup>, Traish A.<sup>3</sup>

**Institutes:**<sup>1</sup>Private Urology Practice, Dept. of Urology, Bremerhaven, Germany, <sup>2</sup>Boston University School of Public Health, Dept. of Epidemiology and Statistics, Boston, United States of America, <sup>3</sup>Boston University School of Medicine, Dept. of Urology and Biochemistry, Boston, United States of America

542

**The effect of non-steroidal anti-inflammatory drugs on risk of benign prostatic hyperplasia**

**By:** Murtola T.<sup>1</sup>, Nygård L.<sup>2</sup>, Talala K.<sup>3</sup>, Taari K.<sup>4</sup>, Tammela T.<sup>1</sup>, Auvinen A.<sup>5</sup>

**Institutes:**<sup>1</sup>Tampere University Hospital, Dept. of Urology, Tampere, Finland, <sup>2</sup>University of Tampere, School of Medicine, Tampere, Finland, <sup>3</sup>Finnish Cancer Registry, Dept. of Research, Helsinki, Finland, <sup>4</sup>Helsinki University Hospital, Dept. of Urology, Helsinki, Finland, <sup>5</sup>University of Tampere, School of Health Sciences, Tampere, Finland

543

**The effect of statins on the risk of receiving transurethral resection of prostate in the outpatients of genitourinary clinic - a study by applying nation-wide population based database**

**By:** Lin C-C.<sup>1</sup>, Chung H.J.<sup>1</sup>, Lin A.T.L.<sup>1</sup>, Huang Y.H.<sup>1</sup>, Chen T.Z.<sup>2</sup>

**Institutes:**<sup>1</sup>Taipei Veterans General Hospital, Dept. of Urology, Taipei, Taiwan, <sup>2</sup>Taipei Veterans General Hospital, Dept. of Family Medicine, Taipei, Taiwan

544

**The comparison in the efficacy of the two combination therapies with an anticholinergic agent and an  $\alpha$  1-blocker versus a  $\alpha$  3-adrenoceptor agonist and an  $\alpha$  1-blocker for patients with benign prostatic enlargement complicated by overactive bladder: A randomized, prospective trial using a urodynamic study**

**By:** Matsukawa Y., Matsuo K., Majima T., Narita H., Kato M., Yamamoto T., Gotoh M.

**Institutes:**Nagoya University Graduate School of Medicine, Dept. of Urology, Nagoya, Japan